$107B in 2+ years? Pfizer’s Covid-19 vaccine may redefine ‘megablockbuster’ by 2022 — analyst
If both its BioNTech-partnered Covid-19 vaccine and in-house antiviral live up to their full promises, Pfizer may be sitting on a $100 billion goldmine in 2022.
That’s according to SVB Leerink analyst Geoffrey Porges, who released his latest forecast early Tuesday complete with a lengthy breakdown of all the intricate factors going into his calculation. Bottom line: universal boosting and pediatric recommendations will shore up global Covid vaccine sales to $59 billion in 2021 and $48 billion in 2022, or $107 billion in cumulative sales.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.